BIOCARDIA INC (BCDA)

Company Profile

BioCardia, Inc. is a clinical-stage biotherapeutic company. The company is headquartered in Sunnyvale, California and currently employs 30 full-time employees. The company is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI); and neurokinin-1 receptor positive (NK1R+) allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced for two clinical indications: the treatment of ischemic HFrEF and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic NK1R+ cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform. Helix delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart.

Company Info

BIOCARDIA INC

320 Soquel Way

Sunnyvale CALIFORNIA 94070

P: 16502260123

CEO: Peter Altman

Employees: 30

Website: https://www.biocardia.com/